AZTA — Azenta, Inc.

Azenta Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $161 million, up 12% year-over-year and 9% organically, exceeding expectations.
• Adjusted EBITDA Margin: Approximately 11.4%, down 60 basis points year-over-year but up 610 basis points sequentially.
• Non-GAAP EPS: $0.16.
• Free Cash Flow: Negative $5 million, impacted by working capital usage and lower deferred revenue.
• Cash Position: Ended the quarter with $529 million in cash, cash equivalents, and marketable securities.
• Guidance Update: Full-year revenue expected between $613 million and $618 million, with organic revenue growth projected to be flat to up 1%.

2. Strategic Updates and Business Highlights

• Multiomics: Delivered year-over-year growth, driven by improved execution and customer engagement, particularly in North America, Europe, and China.
• Sample Management Solutions: Strong performance in biorepositories and C&I, contributing to overall revenue stability.
• Operational Transformation: Continued focus on restructuring and optimizing the Multiomics business, including footprint rationalization and enhancing high-value workflows.
• Automated Stores: Progress made in addressing quality issues, with remediation completed on previously identified systems.
• Divestiture of B Medical Systems: Completed on July 1, 2026, simplifying the portfolio and focusing on core Life Sciences businesses.

3. Forward Guidance and Outlook

• Fourth Quarter Guidance: Organic revenue expected to decline low single digits, with adjusted EBITDA projected between $20 million and $23 million.
• Fiscal 2027 Outlook: Not provided, but management indicated cautious optimism based on improved customer engagement and market conditions.
• Long-term Goals: Continued focus on scaling biorepositories and Multiomics workflows, with expectations for margin improvements in the coming years.

4. Bad News, Challenges, or Points of Concern

• Uneven Market Conditions: Continued caution due to mixed demand environments, particularly in North America where research spending remains below prior year levels.
• Sanger Sequencing: Ongoing headwinds affecting performance, with legacy issues impacting profitability.
• Automated Stores and Cryo Systems: Facing challenges related to capital equipment demand and project timing, leading to unpredictability in order conversion.
• Quality Remediation Costs: Expected total impact of $5 million to $6 million for the fiscal year, affecting margins.

5. Notable Q&A Insights

• Multiomics Performance: Improvement attributed to delayed project catch-up, new leadership in North America, and increased customer activity, though caution remains regarding sustainability.
• Capital Allocation: Management remains disciplined in pursuing strategic M&A while balancing share repurchases and investments in growth.
• Regional Demand Variability: Strong performance in Europe and China contrasted with mixed results in North America, emphasizing the need for targeted strategies in different markets.
• Future Margin Expansion: Management expressed confidence in achieving long-term margin targets, with expectations of continued improvement despite current challenges.

Overall, Azenta's Q3 2026 results reflect a company in transition, with positive revenue growth and strategic initiatives underway, but also facing significant market challenges and operational hurdles that require ongoing attention.